BMYBristol-Myers SquibbSigning up patients
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2/3
- Patients
- 470 (planned)
- Started
- Sep 30, 2025
- Main results expected
- Jan 26, 2029
- Fully finished
- Nov 18, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
Measured over: Approximately 3 months
Phase 3: Progression-Free Survival (PFS)
Measured over: Up to 5 years
Phase 3: Overall Survival (OS)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07106762 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC